Editor's Choice Avastin versus Lucentis BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e3162 (Published 02 May 2012) Cite this as: BMJ 2012;344:e3162 Article Related content Metrics Responses Peer review Related articles Feature Why using Avastin for eye disease is so difficult Published: 01 May 2012; BMJ 344 doi:10.1136/bmj.e3012 Editorial Anti-vascular endothelial growth factor treatment for eye diseases Published: 01 May 2012; BMJ 344 doi:10.1136/bmj.e2970 Analysis Implications of “not me” drugs for health systems: lessons from age related macular degeneration Published: 01 May 2012; BMJ 344 doi:10.1136/bmj.e2941 Letter The scientific community should lobby to be able to apply for drug licences Published: 22 May 2012; BMJ 344 doi:10.1136/bmj.e3553 Letter Beware renal adverse effects of anti-vascular endothelial growth factor treatment Published: 01 June 2012; BMJ 344 doi:10.1136/bmj.e3838 Letter Approve bevacizumab for use in eye disease in cash strapped times Published: 23 July 2012; BMJ 345 doi:10.1136/bmj.e4806 See more The BMJ Christmas appeal 2016-7: Orbis, the sight savers BMJ December 01, 2016, 355 i6425; DOI: https://doi.org/10.1136/bmj.i6425 Leaps in the dark BMJ December 01, 2016, 355 i6447; DOI: https://doi.org/10.1136/bmj.i6447 NHS spent 8% more on medicines last year BMJ November 23, 2016, 355 i6320; DOI: https://doi.org/10.1136/bmj.i6320 Seven days in medicine: 9 to 15 November 2016 BMJ November 17, 2016, 355 i6106; DOI: https://doi.org/10.1136/bmj.i6106 Babies with microcephaly in Brazil are struggling to access care BMJ November 16, 2016, 355 i6157; DOI: https://doi.org/10.1136/bmj.i6157 Cited by... Approve bevacizumab for use in eye disease in cash strapped timesFulltext PDF Beware renal adverse effects of anti-vascular endothelial growth factor treatmentFulltext PDF The scientific community should lobby to be able to apply for drug licencesFulltext PDF
